Loading
Cancer, Hypoxia, and Metabolism / Ferroptosis and Cancer Prognosis · Journal article
Cancer & Metabolism · August 18, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic preclinical study proposing that lactate drives immune evasion in pancreatic cancer via a TRMT6-SIRT5 regulatory axis and that combining CDK4/6 inhibitors with lactate blockers may restore immunotherapy sensitivity in mouse models. The work is exploratory, identifies a putative pathway, and lacks human validation or clinical endpoint data.
Preclinical mechanistic study combining in vitro cell models and xenograft mouse models. PDAC cell lines (unspecified) and xenograft mice derived from PDAC cells.. Intervention: Lactate exposure (in vitro); CDK4/6 inhibitors combined with lactate metabolism blockers (in vivo); anti-PD-1 therapy (in vivo).. Compared with: Untreated or standard single-agent controls (not explicitly detailed in source)..
Lactate enhanced N1-methyladenosine RNA modification by TRMT6 and increased translation of metabolic enzymes Lactate activated SIRT5-mediated desuccinylation, boosting TCA cycle enzyme activity and oxidative metabolism Lactate upregulated PD-L1 via the TRMT6-SIRT5 axis, enhancing CDK4/6 signaling and immune evasion
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Findings suggest a potential combination strategy but are preclinical and should not guide clinical practice. Translation to human PDAC requires Phase 1/2 trials.
Mechanistic study in cell and mouse models identifying a novel lactate-TRMT6-SIRT5 pathway in PDAC; no human trials, clinical efficacy not demonstrated, and findings require translational confirmation.
As stated by the source record.
Findings suggest a potential combination strategy but are preclinical and should not guide clinical practice. Translation to human PDAC requires Phase 1/2 trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and responds poorly to immune checkpoint inhibitors. Lactate is abundant in the tumor microenvironment and is associated with immune evasion. This study examined the regulatory role of lactate and evaluated metabolism-immunity targeting strategies in PDAC. We used PDAC cell models exposed to lactate and xenograft mice, applying N1-methyladenosine RNA immunoprecipitation, ribosome profiling, and transcriptome analyses to examine lactate’s effects via the TRMT6-SIRT5 axis. The efficacy of CDK4/6 inhibitors combined with lactate metabolism blockers was also tested. Lactate significantly enhanced N1-methyladenosine RNA modification by TRMT6, increasing translation of key metabolic enzymes and driving reprogramming. It activated SIRT5-mediated desuccinylation, boosting TCA cycle enzyme activity and oxidative metabolism. Lactate upregulated PD-L1 via the TRMT6-SIRT5 axis, enhancing CDK4/6 signaling and immune evasion. Combining lactate blockers with CDK4/6 inhibitors reduced PD-L1 expression, restored T cell function, and improved anti-PD-1 therapy efficacy in mice. Lactate may promote metabolic reprogramming and immune evasion in PDAC through the TRMT6-SIRT5 axis, linking metabolism, epigenetic regulation, and antitumor immunity. Combining CDK4/6 inhibition with lactate blockade may provide a rationale for improving immunotherapy responses in pancreatic cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.